Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR501
- Development stage
- Unknown
- Lead developer
- Immune Response BioPharma
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
IR501 is a therapeutic vaccine developed for the treatment of rheumatoid arthritis. It consists of a combination of three peptides (Vbeta3, Vbeta14, and Vbeta17) derived from T cell receptors (TCRs), formulated in incomplete Freund's adjuvant (IFA). The mechanism of action is based on targeting autoreactive T cells implicated in the inflammation and joint destruction characteristic of rheumatoid arthritis. By presenting these specific TCR peptides as antigens, IR501 aims to induce immune tolerance or modulate the immune response against pathogenic T cells. Clinical trials have shown that IR501 is safe and well tolerated; it demonstrated statistically significant improvement in disease activity at certain dosages compared to placebo according to American College of Rheumatology criteria. The drug has reached phase 3 clinical development[1][2][3][4][5].
- Brand names
- RAVAXZyvac-RA
- Other names
- Rheumatoid arthritis vaccine
02
Targets
TRBV (T-cell receptor beta variable chain family)
Beyond the preview
Go deeper on IR501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR501.